Concise Analysis of Biologics and Biosimilars World Markets - WBOY.com: Clarksburg, Morgantown: News, Sports, Weather

Concise Analysis of Biologics and Biosimilars World Markets

  • Local NewsMore>>

  • 13 County Coalitions Come Together To Prevent Substance Abuse

    13 County Coalitions Come Together To Prevent Substance Abuse

    Wednesday, April 23 2014 12:00 AM EDT2014-04-23 04:00:20 GMT
    It was all about celebrating recovery at the Clarksburg Baptist Church Tuesday evening .Coalition programs from thirteen different counties came together with some local officials to talk about the importance of preventing substance abuse.
    It was all about celebrating recovery at the Clarksburg Baptist Church Tuesday evening .Coalition programs from thirteen different counties came together with some local officials to talk about the importance of preventing substance abuse.
  • Volunteers Spruce Up Bridgeport Lakes With 'Community Clean Up Day'

    Volunteers Spruce Up Bridgeport Lakes With 'Community Clean Up Day'

    Tuesday, April 22 2014 11:35 PM EDT2014-04-23 03:35:46 GMT
    Tuesday turned out to be a beautiful evening for dozens of Bridgeport residents, who came out in support of Earth Day to spruce up Hinkle and Deegan Lakes.
    Tuesday turned out to be a beautiful evening for dozens of Bridgeport residents, who came out in support of Earth Day to spruce up Hinkle and Deegan Lakes.
  • Senator Rockefeller and Ted Koppel Host a Fireside Chat at WV Wesleyan

    Senator Rockefeller and Ted Koppel Host a Fireside Chat at WV Wesleyan

    Tuesday, April 22 2014 6:40 PM EDT2014-04-22 22:40:43 GMT
    It was a celebratory day at West Virginia Wesleyan College as Senator Jay Rockefeller returned to campus for the first time in nearly eight years in an event with journalist Ted Koppel. 
    It was a celebratory day at West Virginia Wesleyan College as Senator Jay Rockefeller returned to campus for the first time in nearly eight years in an event with journalist Ted Koppel. 

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, February 5, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/9lglrg/biologics_and) has announced the addition of the "Biologics and Biosimilars World Markets" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


Biologics are complex molecules manufactured through cell culture recombinant DNA technology. Biologics additionally comprise recombinant insulin, growth hormone and monoclonal antibodies for treating conditions such as cancer and autoimmunity. Also known as follow-on biologics or subsequent entry biologics (SEBs), biosimilars are to biologics what generics are to branded drugs; they lower healthcare expenditures. This report anticipates that the global biologic drugs market will jump to over $220 billion by 2019.

The study describes the emergence of biologics and biosimilars and their potential role in shaping the future of the global healthcare industry. The study analyzes the changing dynamics of the pharmaceutical market and provides insight into the regulatory pathways for branded pharmaceuticals and biologics, patent expirations, business strategies, clinical trials and drug applications.

Biologics, also known as biopharmaceuticals, can be categorized into three main modalities: therapeutic proteins, monoclonal antibodies and vaccines. Most of the biologic drugs marketed so far are recombinant therapeutic protein drugs, which are used to relieve patients suffering from chronic diseases, such as cancer, diabetes, cardiovascular diseases, infertility and cystic fibrosis. Globally, the U.S. commands 43% of biologics sales, followed by the E.U. (21%) and Japan (9%).

Key biologics and biosimilars are covered by the report, including Humira (Adalimumab), Remicade (Infliximab), Lantus (Insulin Glargine), Levemir (Insulin Detemir), Privigen (Immune Globulin Intravenous), Aranesp (Darbepoetin Alfa), Enbrel (Etanercept), Herceptin (Trastuzumab) and Remicade (Infliximab). Moreover, this report examines companies that are actively developing and marketing biologics and biosimilars in the world. Detailed tables and charts with sales forecasts and marketshare data are also included.


Key Topics Covered: 

1. Overview

2. Pharmaceutical Industry: An Overview

3. Brand Name Pharmaceuticals: A Brief Overview

4. Generic Drugs: A Brief Overview

5. Biologics

6. Biosimilars

7. Company Profiles


Companies Mentioned:

  • AbbVie, Inc
  • Abbott Laboratories
  • Actelion Ltd
  • Amgen, Inc
  • Amoytop Biotech Co, Ltd
  • Anhui Anke Biotechnology (Group) Co, Ltd
  • Apotex, Inc
  • Astellas Pharma, Inc
  • AstraZeneca
  • Bayer AG
  • Beijing Four Rings Biopharmaceuticals
  • Bharat Serums and Vaccines Limited
  • Bio, Inc
  • Biocon Ltd
  • Biogen Idec, Inc
  • Bioton SA
  • Boehringer Ingelheim Pharmaceuticals, Inc
  • Bristol-Myers Squibb, Co
  • Celgene Corporation
  • Celltrion, Inc
  • Cipla Ltd
  • Dr Reddy's Laboratories Ltd
  • Elan Corporation, PLC
  • Eli Lilly & Co
  • Gideon Richter
  • Gilead Sciences, Inc
  • GlaxoSmithKline PLC
  • Hospira, Inc
  • Intas Pharmaceuticals Limited
  • Johnson & Johnson
  • Merck & Co, Inc
  • Mylan, Inc
  • Novartis AG
  • Pfizer, Inc
  • Roche Holdings AG
  • Sandoz International GmbH
  • Sanofi
  • Stada Arzneimittel Aktiengesellschaft
  • Teva Pharmaceutical Industries Limited
  • Watson Pharmaceuticals, Inc


For more information visit http://www.researchandmarkets.com/research/9lglrg/biologics_and


Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net


©2012 PR Newswire. All Rights Reserved.